Skip to main content
Top
Gepubliceerd in: Quality of Life Research 11/2017

20-06-2017

Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20)

Auteurs: Jacobien M. Kieffer, Tjeerd J. Postma, Lonneke van de Poll-Franse, Floortje Mols, Jan J. Heimans, Guido Cavaletti, Neil K. Aaronson, In Collaboration with the CI-PeriNomS Group

Gepubliceerd in: Quality of Life Research | Uitgave 11/2017

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

To investigate the scale structure and psychometrics of the EORTC chemotherapy-induced peripheral neuropathy module (QLQ-CIPN20).

Methods

Using confirmatory factor analyses (CFA), we tested two hypothesized scale structure models of the QLQ-CIPN20 in 473 patients with non-small cell lung cancer, 281 patients with heterogeneous cancer diagnoses, and 500 patients with colorectal cancer. We also modeled the two hypothesized models as bi-factor models. These included a general factor, in addition to the specific domain factors. Additional models were investigated with exploratory factor analysis (EFA). Known groups validity was evaluated where justified.

Results

CFA could not confirm the two hypothesized models (Model 1: CFI < 0.926; TLI < 0.914; RMSEA > 0.077 and Model 2: CFI < 0.906; TLI < 0.887; RMSEA > 0.105) in any of the three samples. Including a general factor to these two hypothesized models to produce a bi-factor model also did not yield satisfactory results. Using EFA, we identified four different factor structures in the three samples that were unstable due to cross loadings of the items. When scoring the QLQ-CIPN20 as a simple, additive checklist evidence was found for known groups validity in the first two samples based on Common Toxicity Criteria (CTC-AE), and in the third sample based on exposure to CIPN-inducing chemotherapy.

Conclusions

Neither CFA nor EFA yielded support for a stable subscale structure for the QLQ-CIPN20. Scoring the questionnaire as a simple additive checklist results in acceptable validity.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
go back to reference Riaz, S. S., & Tomlinson, D. R. (1996). Neurotrophic factors in peripheral neuropathies: Pharmacological strategies. Progress in Neurobiology, 49(2), 125–143.CrossRefPubMed Riaz, S. S., & Tomlinson, D. R. (1996). Neurotrophic factors in peripheral neuropathies: Pharmacological strategies. Progress in Neurobiology, 49(2), 125–143.CrossRefPubMed
2.
go back to reference Miltenburg, N. C., & Boogerd, W. (2014). Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treatment Reviews, 40(7), 872–882.CrossRefPubMed Miltenburg, N. C., & Boogerd, W. (2014). Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treatment Reviews, 40(7), 872–882.CrossRefPubMed
3.
go back to reference Grisold, W., Cavaletti, G., & Windebank, A. J. (2012). Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention. Neuro-Oncology, 14(Suppl 4), iv45–iv54.CrossRefPubMedPubMedCentral Grisold, W., Cavaletti, G., & Windebank, A. J. (2012). Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention. Neuro-Oncology, 14(Suppl 4), iv45–iv54.CrossRefPubMedPubMedCentral
4.
go back to reference Mols, F., Beijers, T., Lemmens, V., van den Hurk, C. J., Vreugdenhil, G., & van de Poll-Franse, L. V. (2013). Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: Results from the population-based PROFILES registry. Journal of Clinical Oncology, 31(21), 2699–2707.CrossRefPubMed Mols, F., Beijers, T., Lemmens, V., van den Hurk, C. J., Vreugdenhil, G., & van de Poll-Franse, L. V. (2013). Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: Results from the population-based PROFILES registry. Journal of Clinical Oncology, 31(21), 2699–2707.CrossRefPubMed
5.
go back to reference Mols, F., Beijers, T., Vreugdenhil, G., & van de Poll-Franse, L. (2014). Chemotherapy-induced peripheral neuropathy and its association with quality of life: A systematic review. Supportive Care in Cancer, 22(8), 2261–2269.CrossRefPubMed Mols, F., Beijers, T., Vreugdenhil, G., & van de Poll-Franse, L. (2014). Chemotherapy-induced peripheral neuropathy and its association with quality of life: A systematic review. Supportive Care in Cancer, 22(8), 2261–2269.CrossRefPubMed
6.
go back to reference Trotti, A., Colevas, A. D., Setser, A., Rusch, V., Jaques, D., Budach, V., et al. (2003). CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars in Radiation Oncology, 13(3), 176–181.CrossRefPubMed Trotti, A., Colevas, A. D., Setser, A., Rusch, V., Jaques, D., Budach, V., et al. (2003). CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars in Radiation Oncology, 13(3), 176–181.CrossRefPubMed
7.
go back to reference Cornblath, D. R., Chaudhry, V., Carter, K., Lee, D., Seysedadr, M., Miernicki, M., et al. (1999). Total neuropathy score: Validation and reliability study. Neurology, 53(8), 1660–1664.CrossRefPubMed Cornblath, D. R., Chaudhry, V., Carter, K., Lee, D., Seysedadr, M., Miernicki, M., et al. (1999). Total neuropathy score: Validation and reliability study. Neurology, 53(8), 1660–1664.CrossRefPubMed
8.
go back to reference Cavaletti, G., Frigeni, B., Lanzani, F., Mattavelli, L., Susani, E., Alberti, P., et al. (2010). Chemotherapy-induced peripheral neurotoxicity assessment: A critical revision of the currently available tools. European Journal of Cancer, 46(3), 479–494.CrossRefPubMed Cavaletti, G., Frigeni, B., Lanzani, F., Mattavelli, L., Susani, E., Alberti, P., et al. (2010). Chemotherapy-induced peripheral neurotoxicity assessment: A critical revision of the currently available tools. European Journal of Cancer, 46(3), 479–494.CrossRefPubMed
9.
go back to reference Basch, E., Iasonos, A., McDonough, T., Barz, A., Culkin, A., Kris, M. G., et al. (2006). Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study. Lancet Oncol, 7(11), 903–909.CrossRefPubMed Basch, E., Iasonos, A., McDonough, T., Barz, A., Culkin, A., Kris, M. G., et al. (2006). Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study. Lancet Oncol, 7(11), 903–909.CrossRefPubMed
10.
go back to reference Alberti, P., Rossi, E., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Frigeni, B., et al. (2014). Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Annals of Oncology, 25(1), 257–264.CrossRefPubMed Alberti, P., Rossi, E., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Frigeni, B., et al. (2014). Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Annals of Oncology, 25(1), 257–264.CrossRefPubMed
11.
go back to reference Hershman, D. L., Lacchetti, C., Dworkin, R. H., Lavoie Smith, E. M., Bleeker, J., Cavaletti, G., et al. (2014). Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 32(18), 1941–1967.CrossRefPubMed Hershman, D. L., Lacchetti, C., Dworkin, R. H., Lavoie Smith, E. M., Bleeker, J., Cavaletti, G., et al. (2014). Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 32(18), 1941–1967.CrossRefPubMed
12.
go back to reference Hausheer, F., Schilsky, R., Bain, S., Berghorn, E., & Lieberman, F. (2006). Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Seminars in Oncology, 33(1), 15–49.CrossRefPubMed Hausheer, F., Schilsky, R., Bain, S., Berghorn, E., & Lieberman, F. (2006). Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Seminars in Oncology, 33(1), 15–49.CrossRefPubMed
13.
go back to reference Shimozuma, K., Ohashi, Y., Takeuchi, A., Aranishi, T., Morita, S., Kuroi, K., et al. (2009). Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC. Support Care Center, 17(12), 1483–1491.CrossRef Shimozuma, K., Ohashi, Y., Takeuchi, A., Aranishi, T., Morita, S., Kuroi, K., et al. (2009). Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC. Support Care Center, 17(12), 1483–1491.CrossRef
14.
go back to reference Land, S., Kopec, J., Cecchini, R., Ganz, P., Wieand, H. S., Colangelo, L., et al. (2007). Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. Journal of Clinical Oncology, 25(16), 2205–2211.CrossRefPubMed Land, S., Kopec, J., Cecchini, R., Ganz, P., Wieand, H. S., Colangelo, L., et al. (2007). Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. Journal of Clinical Oncology, 25(16), 2205–2211.CrossRefPubMed
15.
go back to reference Cella, D., Peterman, A., Hudgens, S., Webster, K., & Socinski, M. (2003). Measuring the side effects of taxane therapy in oncology. Cancer, 98(4), 822–831.CrossRefPubMed Cella, D., Peterman, A., Hudgens, S., Webster, K., & Socinski, M. (2003). Measuring the side effects of taxane therapy in oncology. Cancer, 98(4), 822–831.CrossRefPubMed
16.
go back to reference Kopec, J. A., Land, S. R., Cecchini, R. S., Ganz, P. A., Cella, D., Costantino, J., et al. (2006). Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. Journal of supportive oncology, 4, W1–W8. Kopec, J. A., Land, S. R., Cecchini, R. S., Ganz, P. A., Cella, D., Costantino, J., et al. (2006). Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. Journal of supportive oncology, 4, W1–W8.
17.
go back to reference Driessen, C. M. L., Kleine-Bolt, K. M. E., Vingerhoets, A. J. J. M., Mols, F., & Vreugdenhil, G. (2012). Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients. Supportive Care in Cancer, 20(4), 877–881.CrossRefPubMed Driessen, C. M. L., Kleine-Bolt, K. M. E., Vingerhoets, A. J. J. M., Mols, F., & Vreugdenhil, G. (2012). Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients. Supportive Care in Cancer, 20(4), 877–881.CrossRefPubMed
18.
go back to reference Postma, T. J., Aaronson, N. K., Heimans, J. J., Muller, M. J., Hildebrand, J. G., Delattre, J. Y., et al. (2005). The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. European Journal of Cancer, 41(8), 1135–1139.CrossRefPubMed Postma, T. J., Aaronson, N. K., Heimans, J. J., Muller, M. J., Hildebrand, J. G., Delattre, J. Y., et al. (2005). The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. European Journal of Cancer, 41(8), 1135–1139.CrossRefPubMed
19.
go back to reference Sprangers, M. A. G., Cull, A., Groenvold, M., Bjordal, K., Blazeby, J., & Aaronson, N. K. (1998). The European organization for research and treatment of cancer approach to developing questionnaire modules: An update and overview. Quality of Life Research, 7(4), 291–300.CrossRefPubMed Sprangers, M. A. G., Cull, A., Groenvold, M., Bjordal, K., Blazeby, J., & Aaronson, N. K. (1998). The European organization for research and treatment of cancer approach to developing questionnaire modules: An update and overview. Quality of Life Research, 7(4), 291–300.CrossRefPubMed
20.
go back to reference Cavaletti, G., Bogliun, G., Marzorati, L., Zincone, A., Piatti, M., Colombo, N., et al. (2003). Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology, 61(9), 1297–1300.CrossRefPubMed Cavaletti, G., Bogliun, G., Marzorati, L., Zincone, A., Piatti, M., Colombo, N., et al. (2003). Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology, 61(9), 1297–1300.CrossRefPubMed
21.
go back to reference Wolf, S., Barton, D., Qin, R., Wos, E., Sloan, J., Liu, H., et al. (2012). The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Supportive Care in Cancer, 20(3), 625–632.CrossRefPubMed Wolf, S., Barton, D., Qin, R., Wos, E., Sloan, J., Liu, H., et al. (2012). The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Supportive Care in Cancer, 20(3), 625–632.CrossRefPubMed
22.
go back to reference Lavoie Smith, E., Barton, D., Qin, R., Steen, P., Aaronson, N., & Loprinzi, C. (2013). Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Quality of Life Research, 22(10), 2787–2799.CrossRefPubMedPubMedCentral Lavoie Smith, E., Barton, D., Qin, R., Steen, P., Aaronson, N., & Loprinzi, C. (2013). Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Quality of Life Research, 22(10), 2787–2799.CrossRefPubMedPubMedCentral
23.
go back to reference Cavaletti, G., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Rossi, E., Frigeni, B., et al. (2013). The chemotherapy-induced peripheral neuropathy outcome measures standardization study: From consensus to the first validity and reliability findings. Annals of Oncology, 24(2), 454–462.CrossRefPubMed Cavaletti, G., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Rossi, E., Frigeni, B., et al. (2013). The chemotherapy-induced peripheral neuropathy outcome measures standardization study: From consensus to the first validity and reliability findings. Annals of Oncology, 24(2), 454–462.CrossRefPubMed
24.
go back to reference Hausheer, F. H., Kanter, P., Cao, S., Haridas, K., Seetharamulu, P., Reddy, D., et al. (1998). Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents. Seminars in Oncology, 25(5), 584–599.PubMed Hausheer, F. H., Kanter, P., Cao, S., Haridas, K., Seetharamulu, P., Reddy, D., et al. (1998). Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents. Seminars in Oncology, 25(5), 584–599.PubMed
25.
go back to reference Reilly, R. T. (2004). BNP-7787 (BioNumerik/Baxter Oncology/Grelan). IDrugs, 7(1), 64–69.PubMed Reilly, R. T. (2004). BNP-7787 (BioNumerik/Baxter Oncology/Grelan). IDrugs, 7(1), 64–69.PubMed
26.
go back to reference Trotti, A., Byhardt, R., Stetz, J., Gwede, C., Corn, B., Fu, K., et al. (2000). Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. International Journal of Radiation Oncology * Biology *Physics, 47(1), 13–47.CrossRef Trotti, A., Byhardt, R., Stetz, J., Gwede, C., Corn, B., Fu, K., et al. (2000). Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. International Journal of Radiation Oncology * Biology *Physics, 47(1), 13–47.CrossRef
27.
go back to reference Muthén, L. K., & Muthén, B. O. (1998–2010). Mplus User’s Guide (6th ed.). Los Angeles, CA: Muthén & Muthén. Muthén, L. K., & Muthén, B. O. (1998–2010). Mplus User’s Guide (6th ed.). Los Angeles, CA: Muthén & Muthén.
29.
go back to reference Flora, D., & Curran, P. (2004). An empirical evaluation of alternative methods of estimation for confirmatory factor analysis with ordinal data. Psychological Methods, 9(4), 466.CrossRefPubMedPubMedCentral Flora, D., & Curran, P. (2004). An empirical evaluation of alternative methods of estimation for confirmatory factor analysis with ordinal data. Psychological Methods, 9(4), 466.CrossRefPubMedPubMedCentral
30.
go back to reference Reise, S. P., Morizot, J., & Hays, R. D. (2007). The role of the bifactor model in resolving dimensionality issues in health outcomes measures. Quality of Life Research, 16(Suppl 1), 19–31.CrossRefPubMed Reise, S. P., Morizot, J., & Hays, R. D. (2007). The role of the bifactor model in resolving dimensionality issues in health outcomes measures. Quality of Life Research, 16(Suppl 1), 19–31.CrossRefPubMed
31.
go back to reference Reise, S. P., Moore, T. M., & Haviland, M. G. (2010). Bifactor models and rotations: Exploring the extent to which multidimensional data yield univocal scale scores. Journal of Personality Assessment, 92(6), 544–559.CrossRefPubMedPubMedCentral Reise, S. P., Moore, T. M., & Haviland, M. G. (2010). Bifactor models and rotations: Exploring the extent to which multidimensional data yield univocal scale scores. Journal of Personality Assessment, 92(6), 544–559.CrossRefPubMedPubMedCentral
32.
go back to reference Schermelleh-Engel, K., Moosbrugger, H., & Muller, H. (2003). Evaluating the fit of structural equation models: Tests of significance and descriptive goodness-of-fit measures. Methods of Psychological Research-Online, 8, 23–74. Schermelleh-Engel, K., Moosbrugger, H., & Muller, H. (2003). Evaluating the fit of structural equation models: Tests of significance and descriptive goodness-of-fit measures. Methods of Psychological Research-Online, 8, 23–74.
33.
go back to reference Ferguson, E., & Cox, T. (1993). Exploratory factor analysis: A users’guide. International Journal of Selection and Assessment, 1(2), 84–94.CrossRef Ferguson, E., & Cox, T. (1993). Exploratory factor analysis: A users’guide. International Journal of Selection and Assessment, 1(2), 84–94.CrossRef
34.
go back to reference Cattell, R. B., & Vogelmann, S. (1977). A comprehensive trial of the scree and kg criteria for determining the number of factors. Multivariate Behavioral Research, 12(3), 289–325.CrossRefPubMed Cattell, R. B., & Vogelmann, S. (1977). A comprehensive trial of the scree and kg criteria for determining the number of factors. Multivariate Behavioral Research, 12(3), 289–325.CrossRefPubMed
35.
go back to reference Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., Bottomley, A., on behalf of the EORTC Quality of Life Group and of the Quality of Life Unit. (2001). EORTC QLQ-C30 Scoring Manual (3rd ed.). Brussels EORTC. Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., Bottomley, A., on behalf of the EORTC Quality of Life Group and of the Quality of Life Unit. (2001). EORTC QLQ-C30 Scoring Manual (3rd ed.). Brussels EORTC.
36.
go back to reference Šidák, Z. (1967). Rectangular confidence regions for the means of multivariate normal distributions. Journal of the American Statistical Association, 62(318), 626–633. Šidák, Z. (1967). Rectangular confidence regions for the means of multivariate normal distributions. Journal of the American Statistical Association, 62(318), 626–633.
37.
go back to reference Cersosimo, R. (2005). Oxaliplatin-associated neuropathy: A review. The Annals of Pharmacotherapy, 39(1), 128–135.CrossRefPubMed Cersosimo, R. (2005). Oxaliplatin-associated neuropathy: A review. The Annals of Pharmacotherapy, 39(1), 128–135.CrossRefPubMed
38.
go back to reference Cohen, J. (1977). Statistical power analysis for the behavioural sciences (revised ed.). New York: Academic Press Cohen, J. (1977). Statistical power analysis for the behavioural sciences (revised ed.). New York: Academic Press
39.
go back to reference Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003). Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Medical Care, 41(5), 582–592.PubMed Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003). Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Medical Care, 41(5), 582–592.PubMed
40.
go back to reference Egan, M., Burke, E., Meskell, P., MacNeela, P., & Dowling, M. (2015). Quality of life and resilience related to chemotherapy-induced peripheral neuropathy in patients post treatment with platinums and taxanes. Journal of Research in Nursing. doi:10.1177/1744987115574296. Egan, M., Burke, E., Meskell, P., MacNeela, P., & Dowling, M. (2015). Quality of life and resilience related to chemotherapy-induced peripheral neuropathy in patients post treatment with platinums and taxanes. Journal of Research in Nursing. doi:10.​1177/​1744987115574296​.
41.
go back to reference Loprinzi, C. L., Qin, R., Dakhil, S. R., Fehrenbacher, L., Flynn, K. A., Atherton, P., et al. (2014). Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). Journal of Clinical Oncology, 32(10), 997–1005.CrossRefPubMed Loprinzi, C. L., Qin, R., Dakhil, S. R., Fehrenbacher, L., Flynn, K. A., Atherton, P., et al. (2014). Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). Journal of Clinical Oncology, 32(10), 997–1005.CrossRefPubMed
42.
go back to reference Fayers, P., & Hand, D. (2002). Causal variables, indicator variables and measurement scales: An example from quality of life. Journal of the Royal Statistical Society: Series A (Statistics in Society), 165(2), 233–253.CrossRef Fayers, P., & Hand, D. (2002). Causal variables, indicator variables and measurement scales: An example from quality of life. Journal of the Royal Statistical Society: Series A (Statistics in Society), 165(2), 233–253.CrossRef
43.
go back to reference Kieffer, J., Verrips, E., & Hoogstraten, J. (2009). Model specification in oral health-related quality of life research. European Journal of Oral Sciences, 117(5), 481–484.CrossRefPubMed Kieffer, J., Verrips, E., & Hoogstraten, J. (2009). Model specification in oral health-related quality of life research. European Journal of Oral Sciences, 117(5), 481–484.CrossRefPubMed
44.
go back to reference Fayers, P. M., & Hand, D. J. (1997). Factor analysis, causal indicators and quality of life. Quality of Life Research, 6(2), 139–150.CrossRefPubMed Fayers, P. M., & Hand, D. J. (1997). Factor analysis, causal indicators and quality of life. Quality of Life Research, 6(2), 139–150.CrossRefPubMed
45.
go back to reference Sprangers, M. A. G., te Velde, A., & Aaronson, N. K. (1999). The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European Journal of Cancer, 35(2), 238–247.CrossRefPubMed Sprangers, M. A. G., te Velde, A., & Aaronson, N. K. (1999). The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European Journal of Cancer, 35(2), 238–247.CrossRefPubMed
46.
go back to reference Fayers, P. M., Hand, D. J., Bjordal, K., & Groenvold, M. (1997). Causal indicators in quality of life research. Quality of Life Research, 6(5), 393–406.CrossRefPubMed Fayers, P. M., Hand, D. J., Bjordal, K., & Groenvold, M. (1997). Causal indicators in quality of life research. Quality of Life Research, 6(5), 393–406.CrossRefPubMed
47.
go back to reference Velikova, G., Booth, L., Smith, A. B., Brown, P. M., Lynch, P., Brown, J. M., et al. (2004). Measuring quality of life in routine oncology practice improves communication and patient well-being: A randomized controlled trial. Journal of Clinical Oncology, 22(4), 714–724.CrossRefPubMed Velikova, G., Booth, L., Smith, A. B., Brown, P. M., Lynch, P., Brown, J. M., et al. (2004). Measuring quality of life in routine oncology practice improves communication and patient well-being: A randomized controlled trial. Journal of Clinical Oncology, 22(4), 714–724.CrossRefPubMed
48.
go back to reference Hilarius, D. L., Kloeg, P. H., Gundy, C. M., & Aaronson, N. K. (2008). Use of health-related quality-of-life assessments in daily clinical oncology nursing practice: A community hospital-based intervention study. Cancer, 113(3), 628–637.CrossRefPubMed Hilarius, D. L., Kloeg, P. H., Gundy, C. M., & Aaronson, N. K. (2008). Use of health-related quality-of-life assessments in daily clinical oncology nursing practice: A community hospital-based intervention study. Cancer, 113(3), 628–637.CrossRefPubMed
49.
go back to reference Ruland, C. M., Holte, H. H., Røislien, J., Heaven, C., Hamilton, G. A., Kristiansen, J., et al. (2010). Effects of a computer-supported interactive tailored patient assessment tool on patient care, symptom distress, and patients’ need for symptom management support: a randomized clinical trial. Journal of the American Medical Informatics Association, 17(4), 403–410.CrossRefPubMedPubMedCentral Ruland, C. M., Holte, H. H., Røislien, J., Heaven, C., Hamilton, G. A., Kristiansen, J., et al. (2010). Effects of a computer-supported interactive tailored patient assessment tool on patient care, symptom distress, and patients’ need for symptom management support: a randomized clinical trial. Journal of the American Medical Informatics Association, 17(4), 403–410.CrossRefPubMedPubMedCentral
50.
go back to reference Kluetz, P. G., Slagle, A., Papadopoulos, E., Johnson, L. L., Donoghue, M., Kwitkowski, V. E., et al. (2016). Focusing on core patient-reported outcomes in cancer clinical trials: Symptomatic adverse events, physical function, and disease-related symptoms. Clinical Cancer Research, 22(7), 1553–1558.CrossRefPubMed Kluetz, P. G., Slagle, A., Papadopoulos, E., Johnson, L. L., Donoghue, M., Kwitkowski, V. E., et al. (2016). Focusing on core patient-reported outcomes in cancer clinical trials: Symptomatic adverse events, physical function, and disease-related symptoms. Clinical Cancer Research, 22(7), 1553–1558.CrossRefPubMed
Metagegevens
Titel
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20)
Auteurs
Jacobien M. Kieffer
Tjeerd J. Postma
Lonneke van de Poll-Franse
Floortje Mols
Jan J. Heimans
Guido Cavaletti
Neil K. Aaronson
In Collaboration with the CI-PeriNomS Group
Publicatiedatum
20-06-2017
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 11/2017
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-017-1626-1

Andere artikelen Uitgave 11/2017

Quality of Life Research 11/2017 Naar de uitgave